Melatonin inhibits human
breast cancer cells stimulated with
estrogen. This antiproliferative action depends on the presence of the
estrogen receptor alpha (ERα) in the human MCF-7 cell line and is strictly dose-dependent. Since researchers concerned with
melatonin and
breast cancer have not considered the relevance of the
ubiquitin-
proteasome system to this research in this review we do so. The fact that the first
breast cancer susceptibility gene to be identified, Brca1, functions as a
ubiquitin ligase indicates that the
ubiquitin-
proteasome system has a role in regulating susceptibility to
breast cancer. While mutations of this gene increase the incidence of
breast cancer, the wild type gene suppresses
estrogen-dependent transcriptional events relying on the
estrogen receptor ERα. Three other
ubiquitin ligases,
SCF(Skp2), E6AP and APC, interact directly with ERα at the ERE and
AP-1 promoters of ERα target genes.
Melatonin, like
proteasome inhibitors, decreases
estrogen-induced gene transcription. Indeed, it has been reported that
melatonin specifically inhibits
estrogen-induced transcription mediated by ERα at the ERE and AP1 gene promoters. Herein, we present a model in which the inhibitory action of
melatonin on MCF-7 cells is mediated, directly or indirectly, by the
ubiquitin-
proteasome system. In this model ERα, apoptotic
proteins, and
cell cycle proteins, all influenced by
melatonin, are substrates of key
ubiquitin ligases including
SCF(Skp2), E6AP, and SCF(B-TrCP). Since dysfunction of the
ubiquitin-
proteasome system is a risk factor for
breast cancer, this model provides a context in which to test the clinical potential, and limitations, of
melatonin and
proteasome inhibitors.